<DOC>
	<DOCNO>NCT01721681</DOCNO>
	<brief_summary>The primary objective study assess efficacy FACTOR X prevention bleed give routine prophylaxis 12 month . The secondary objective study : 1 . To assess pharmacokinetics FACTOR X single dose 50 IU/kg . 2 . To assess safety FACTOR X give routine prophylaxis 6 month ( 26 week ) .</brief_summary>
	<brief_title>A Study Investigate BPL 's Factor X Prophylaxis Bleeding Children &lt; 12 Years</brief_title>
	<detailed_description />
	<mesh_term>Factor X Deficiency</mesh_term>
	<criteria>Inclusion Criteria 1 . Children hereditary severe moderate FX deficiency ( FX : C &lt; 5 IU/dL ) , base low reliable FX : C record . 2 . Children 12 year old , whose parent/guardian give informed consent . 3 . Children history severe bleeding e.g . : intracranial haemorrhage , start prophylactic therapy , OR mutation F10 gene cause document severe bleed phenotype . Exclusion Criteria 1 . Children must suffer clinically significant liver disease , renal disease , coagulopathy thrombophilia 2 . Children must history suspicion inhibitor factor X . 3 . Children know suspected hypersensitivity investigational medicinal product excipients . 4 . Children history unreliability noncooperation . 5 . Children participate take part another trial within last 30 day . 6 . Children plan 4 week ' continuous absence locality investigational site , Screening Visit End Study Visit approximately 6 month ( 26 week ) postBaseline .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>